Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Siminder Kaur Atwal"'
Autor:
Constantine S. Tam, Siminder Kaur Atwal, Tycel Phillips, Jane Huang, William Novotny, David Simpson, Judith Trotman, Stephen Opat, Simon Rule, Won Seog Kim, Rachel Wei, Gavin Cull, Michael Wang, Javier Munoz
Publikováno v:
Blood Adv
Zanubrutinib, a highly selective Bruton tyrosine kinase inhibitor, was evaluated in a phase 1/2 study in patients with various B-cell malignancies. In the subgroup of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), zanubrutinib wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dfeb5d25b8f7acfd54b67172a1cb147a
https://europepmc.org/articles/PMC8270663/
https://europepmc.org/articles/PMC8270663/
Autor:
Constantine S. Tam, William Novotny, Gavin Cull, Judith Trotman, Ziwen Tan, Siminder Kaur Atwal, Jane Huang, Eric Holmgren, Paula Marlton, David Gottlieb, Alessandra Tedeschi, David Simpson, James Hilger, Stephen Opat, Andrew W. Roberts, Javier Munoz, Yiling Yu, John F Seymour
Publikováno v:
Blood
Inhibitors of Bruton’s tyrosine kinase (BTK) have established therapeutic activity in patients with Waldenström macroglobulinemia (WM). Zanubrutinib, a potent and selective BTK inhibitor, was evaluated in a phase 1/2 study in patients with WM who
Autor:
Jane Huang, William Novotny, Constantine S. Tam, Alessandra Tedeschi, Aileen Cohen, Véronique Leblond, Siminder Kaur Atwal, Christian Buske, Roger G. Owen
Publikováno v:
Future Oncology. 14:2229-2237
Waldenström macroglobulinemia (WM), an incurable B-cell malignancy, is sensitive to Bruton tyrosine kinase (BTK) inhibition with ibrutinib, a first-generation BTK inhibitor. Off-target effects of ibrutinib against TEC- and EGFR-family kinases are im
Autor:
Krish Patel, Veronika Bachanova, Wong Lilly L, Ian W. Flinn, Prutha Shah, Yu-Waye Chu, Siminder Kaur Atwal, Paolo Strati, Rebecca Elstrom, Bahram Valamehr, Peter Szabo, Jae H. Park, Cara Bickers, Carol Wong, Armin Ghobadi
Publikováno v:
Blood. 138:823-823
Background: The use of a clonal master engineered induced pluripotent stem cell (iPSC) line as a renewable source for the mass production of immune effector cells offers distinct advantages over existing patient (pt)- and donor-derived cell-based can
Autor:
Cara Bickers, Yu-Waye Chu, John M. Pagel, Aaron M. Goodman, Paolo Strati, Wong Lilly L, Krish Patel, Peter Szabo, Veronika Bachanova, Kelly Griffis, Siminder Kaur Atwal, Marlisa Anderson, Rebecca Elstrom
Publikováno v:
Blood. 138:3873-3873
Background: Allogeneic natural killer (NK) cell therapies have documented anti-tumor activity in patients with relapsed/refractory (R/R) hematologic malignancies, including B-cell lymphoma (BCL), and may offer an improved safety profile characterized
Autor:
Veronika Bachanova, Sarah Cooley, Christina Ly, Cara Bickers, Januario E. Castro, Siminder Kaur Atwal, Aaron M. Goodman, John M. Pagel, Daniel Fremgen, Paolo Strati, Kelly Griffis, Marlisa Anderson, Krish Patel, Rebecca Elstrom
Publikováno v:
Journal of Clinical Oncology. 39:7541-7541
7541 Background: FT516 is an investigational, NK cell cancer immunotherapy derived from a clonal master iPSC line. FT516 is engineered with a novel hnCD16 Fc receptor, demonstrated preclinically to maximize antibody-dependent cellular cytotoxicity (Z
Autor:
Stephen Opat, Ziwen Tan, Alessandra Tedeschi, David Ritchie, Judith Trotman, Andrew W. Roberts, William Novotny, Jane Huang, David Simpson, Javier Munoz, Paula Marlton, John F. Seymour, Gavin Cull, Siminder Kaur Atwal, David Gottlieb, Emma Verner, Eric Holmgren, Constantine S. Tam
Publikováno v:
Journal of Clinical Oncology. 38:8051-8051
8051 Background: Inhibitors of Bruton tyrosine kinase (BTK) have established therapeutic activity in patients with WM. Zanubrutinib, a potent and selective BTK inhibitor was evaluated in a phase 1/2 study in treatment-naïve (TN) and relapsed/refract
Autor:
David Simpson, Constantine S. Tam, Javier Munoz, Judith Trotman, Siminder Kaur Atwal, Stephen Opat, Paula Marlton, Ken Wu, David Gottlieb, Jan A. Burger, William Novotny, Jane Huang, Andrew W. Roberts, John F. Seymour, Gavin Cull
Publikováno v:
Blood. 134:500-500
Background: Bruton tyrosine kinase (BTK) plays a critical role in B-cell receptor signaling. Inhibition of BTK has emerged as a strategy for targeting B-cell malignancies including CLL/SLL. Zanubrutinib (BGB-3111) is an investigational, next-generati